Nektar Therapeutics (NKTR) Net Margin (2010 - 2026)

Nektar Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 397.33% for Q1 2026.

• In Q1 2026, Net Margin rose 4647.0% year-over-year to 397.33%; the TTM figure through Mar 2026 stood at 211.63% (down 9267.0% YoY), while the FY2025 annual figure was 219.08%, down 12341.0% from the prior year.
• Net Margin for Q1 2026 stood at 397.33%, down from 1.77% in the prior quarter.
• The five-year high for Net Margin was 109.87% in Q4 2024, with the low at 736.94% in Q2 2022.
• The 5-year median for Net Margin is 249.39% (2023), against an average of 260.98%.
• The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 142303 bps in 2022, then surged 48755 bps in 2023.
• Nektar Therapeutics' Net Margin stood at 91.6% in 2022, then slumped by 292 bps to 176.17% in 2023, then surged by 162 bps to 109.87% in 2024, then tumbled by 102 bps to 1.77% in 2025, then sank by 22347 bps to 397.33% in 2026.
• Business Quant data shows NKTR's Net Margin at 397.33% in Q1 2026, 1.77% in Q4 2025, and 296.76% in Q3 2025.